discovering new anti-infectives
through deep phenotypic insights and machine learning
The "silent pandemic" is no longer silent.
Antimicrobial resistance (AMR) leading to drug-resistant infections is now a recognized and growing global health crisis. The limited pipeline of new drugs to treat the increase in drug resistant infections is a significant global concern.
Discovering new classes of anti-infectives to overcome drug resistant infections.
Our machine learning (ML)-based imaging platform for anti-infective drug discovery enables rapid and highly efficient identification of compounds with new and unexploited mechanisms of action at the very outset of the discovery process.
Our combined expertise, cutting edge technologies and novel workflows enable a rapid and early understanding of a compound’s mechanism of action, the potential addressable target product profile, and clinical utility based on deep analysis of cell behavior.Explore Platform
Delivering new classes of anti-infectives.
ArrePath is applying its technology platform to develop a pipeline of new classes of antibiotics,
targeting unexploited and under-exploited mechanisms of action, to address unmet clinical need and overcome drug resistance.
Recent News and Updates
ArrePath today announced the appointment of Michael Dudley, PharmD, as Chairman of the Company’s Board of Directors.03-24-2022
ArrePath Announces $20 Million Seed Financing to Advance its Machine Learning-based Platform for Discovery of Novel Anti-infectives Addressing Antimicrobial Resistance
ArrePath announced today that it has raised $20 million in seed financing to advance its proprietary, machine learning (ML)-based platform for the discovery of new classes of anti-infectives to overcome antimicrobial resistance (AMR).03-03-2022
ArrePath will be at the 2022 Gordon Research Conference on New Antibacterial Discovery and Development happening July 24 – 29, 2022.03-02-2022